Novartis has secured European Commission approval for Itvisma, a treatment for spinal muscular atrophy, while Biogen's Salanersen has received FDA Breakthrough Therapy designation for the same condition. Research continues linking brain atrophy patterns to neurodegenerative disease progression.
·Novartis wins EU approval for Itvisma to treat spinal muscular atrophy
·Biogen's experimental SMA drug Salanersen granted FDA Breakthrough Therapy status
·Atrophy patterns in preclinical Alzheimer's disease predict longitudinal cognitive decline
·Young Utah girl with spinal muscular atrophy becomes honorary Monster Jam driver
·High school graduate with rare disease defies 10% survival odds
drawn from PharmaTimes, Seeking Alpha, Yahoo Finance, ABC4 Utah · updated 16h ago